Psychiatry & Neurology Doctors in Temple, TX Accepting Medicare

124 Psychiatry & Neurology doctors found. Showing 121 - 124

Dr. Nicole Danielle Gutierrez, M.D. Psychiatry & Neurology - Psychiatry Medicare: Accepting Medicare Assignments Practice Location: 2401 S 31st St, Temple, TX 76508 Phone: 254-724-2111

Dr. Naim Ahmed Memon, M.D. Psychiatry & Neurology - Psychiatry Medicare: Accepting Medicare Assignments Practice Location: 2401 S 31st St, Temple, TX 76508 Phone: 254-724-2111

Dr. Muhammad Rehan Azher Puri, M.D. Psychiatry & Neurology - Psychiatry Medicare: Accepting Medicare Assignments Practice Location: 2401 S 31st St, Temple, TX 76508 Phone: 254-724-2111

Chris Chikazu Tokunaga, M.D. Psychiatry & Neurology - Addiction Medicine Medicare: Medicare Enrolled Practice Location: 2401 S 31st St, Temple, TX 76508 Phone: 254-724-2111

News Archive

Younger people with HIV feel more isolated and stressed than older people

Case Western Reserve University researchers were surprised to learn that people younger than 50 years old with HIV feel more isolated and stressed than older people with the disease. They expected their study to reveal just the opposite.

Foot assessments can help detect atrial fibrillation in patients with diabetes

Atrial fibrillation can be detected during annual foot assessments in patients with diabetes, according to research presented today at EHRA 2021, an online scientific congress of the European Society of Cardiology (ESC).

Moberg Pharma agrees to acquire three OTC brands in the U.S. from Bayer HealthCare

Moberg Pharma AB has signed a deal to acquire three well established Over-The-Counter brands in the U.S. from Bayer HealthCare, LLC. Total annual sales for the brands are approximately 20 MSEK (ca 3 m$). The purchase price is 32 MSEK (4.8 m$) and is financed by available cash resources.

Charles River Laboratories International, WuXi PharmaTech sign definitive agreement to combine

Charles River Laboratories International, Inc., a leading global provider of research models and associated services and of preclinical drug development services, and WuXi PharmaTech, a leading drug research and development outsourcing company with expertise in discovery chemistry and with operations in China and the United States, today announced that they have signed a definitive agreement under which Charles River and WuXi will combine in a cash and stock transaction valued at approximately $1.6 billion.

Read more Medical News

› Verified 3 days ago

• 1
• 2
• 3
• 4
• 5
• 6
• 7(current)